IP Library Granted Patent US 6,861,409
Granted Patent B2
US 6,861,409 · App. 09/880,498 · Granted Mar 1, 2005

Growth hormone secretagogues

Assignee: Zentaris AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,861,409
App. No.
09/880,498
Granted
Mar 1, 2005
Kind
B2
Abstract

The invention relates to compounds of formula I which are useful for elevating the plasma level of growth hormone in a mammal as well for the treatment of growth hormone secretion deficiency, growth retardation in child and metabolic disorders associated with growth hormone secretion deficiency.

Claims (9)

1. A compound which is

2. A pharmaceutical composition, comprising a compound of claim 1 .

3. The composition of claim 2 , in combination with a pharmaceutically acceptable carrier.

4. The composition of claim 2 , in combination with an additional growth hormone secretagogue.

5. A method for elevating the plasma level of growth hormone in a mammal comprising administering to a mammal a therapeutically effective amount of a compound according to claim 1 so as to elevate the plasma level of growth hormone.

6. A method for the treatment of growth hormone secretion deficiency comprising administering to a mammal a therapeutically effective amount of a compound according to claim 1 so as to treat the growth hormone secretion deficiency.

7. A method for the treatment of growth retardation in a child comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 so as to treat the growth retardation.

8. A method for the treatment of metabolic disorders associated with growth hormone secretion deficiency comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 so as to treat the metabolic disorder.

9. The compound of claim 1 in the form a salt thereof.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS ON THE NOTICE OF RECORDATION OF CHANGE OF NAME TO READ --WEISMULLERSTRASSE 50-- PREVIOUSLY RECORDED ON REEL 028743 FRAME 0539. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR'S INTEREST. Recorded Feb 28, 2013
From: ZENTARIS AG (A/K/A ZENTARIS GMBH)
To: AETERNA ZENTARIS GMBH
Reel/Frame 029901/0268 →
TERMINATION OF LICENSE AGREEMENT Recorded Oct 31, 2012
From: ARDANA BIOSCIENCE LIMITED
To: AETERNA ZENTARIS GMBH
Reel/Frame 029227/0573 →
CHANGE OF NAME Recorded Aug 7, 2012
From: ZENTARIS AG (A/K/A ZENTARIS GMBH)
To: AETERNA ZENTARIS GMBH
Reel/Frame 028743/0539 →
FORMAL LICENSE AGREEMENT Recorded Jun 2, 2003
From: ZENTARIS AG
To: ARDANA BIOSCIENCE LIMITED
Reel/Frame 014123/0798 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2001
From: MARTINEZ, JEAN; FEHRENTZ, JEAN-ALAIN; GUERLAVAIS, VINCENT
To: ZENTARIS AG
Reel/Frame 012250/0280 →
Continuity (3)
Provisional Application 6023492800 · Sep 26, 2000
Provisional Application 6021132600 · Jun 13, 2000
Related Publication 20020165343A1 · Nov 7, 2002